APA (7th ed.) Citation

Jaspers, T. C. C., Meijer, C. E., Vleming, L. J., Franssen, C. F. M., Diepstraten, J., Lukens, M. V., . . . Koomen, J. V. (2022). Optimising the Nadroparin Dose for Thromboprophylaxis During Hemodialysis by Developing a Population Pharmacodynamic Model Using Anti-Xa Levels. Clinical pharmacokinetics, 61(11), 1559-1569. https://doi.org/10.1007/s40262-022-01162-x

Chicago Style (17th ed.) Citation

Jaspers, Tessa C. C., et al. "Optimising the Nadroparin Dose for Thromboprophylaxis During Hemodialysis by Developing a Population Pharmacodynamic Model Using Anti-Xa Levels." Clinical Pharmacokinetics 61, no. 11 (2022): 1559-1569. https://doi.org/10.1007/s40262-022-01162-x.

MLA (9th ed.) Citation

Jaspers, Tessa C. C., et al. "Optimising the Nadroparin Dose for Thromboprophylaxis During Hemodialysis by Developing a Population Pharmacodynamic Model Using Anti-Xa Levels." Clinical Pharmacokinetics, vol. 61, no. 11, 2022, pp. 1559-1569, https://doi.org/10.1007/s40262-022-01162-x.